Hong Kong digital marketing company MediaOn Group (MEON.US) sets IPO price at $4-6 per share, aiming to raise $20 million.
Digital marketing and advertising solutions provider MediaOn Group (MEON.US), headquartered in Hong Kong, submitted documents to the U.S. Securities and Exchange Commission on Wednesday, planning to raise up to $20 million through an initial public offering.
Hong Kong-based digital marketing and advertising solutions provider MediaOn Group (MEON.US) submitted documents to the US Securities and Exchange Commission on Wednesday, planning to raise up to $20 million through an initial public offering. The company intends to issue 3.9 million shares at a price of $4 to $6 per share, with 49% being secondary shares, aiming to raise $20 million. Based on the midpoint of the offering price range, MediaOn Group's market value will reach $110 million.
MediaOn's business mainly includes three major areas: marketing campaigns, media rebates, and media placement. The company has completed over 3000 marketing campaigns across industries such as finance, retail, and technology. Through its proprietary platforms WeShare.hk and Sodainsight (providing influencer marketing, social media sentiment monitoring, and interactive digital solutions), the company can receive media rebates equivalent to 5% to 30% of qualified advertising expenditures. Additionally, MediaOn also provides large-scale event production services to brands, PR agencies, and third-party marketing companies through joint ventures and partnerships.
Founded in 2011, the company achieved revenue of $2 million in the 12 months ending on March 31, 2025. MediaOn previously confidentially filed for an IPO on the NASDAQ stock exchange with the stock symbol "MEON" on May 12, 2025. Joseph Stone Capital is the sole book-running manager for this transaction.
Related Articles

HaiChuang Pharmaceuticals (688302.SH)Daon Zalu Amin soft capsules have been included in the 2025 National Medical Insurance Drug List.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH)Innovative drugs Avimeplanib and Golirelin included in the new version of the national medical insurance directory.
.png)
Zejing Pharmaceutical (688266.SH): Gicacizidine hydrochloride tablets included in the 2025 National Medical Insurance Drug List.
HaiChuang Pharmaceuticals (688302.SH)Daon Zalu Amin soft capsules have been included in the 2025 National Medical Insurance Drug List.

Shanghai Allist Pharmaceuticals Co., Ltd. (688578.SH)Innovative drugs Avimeplanib and Golirelin included in the new version of the national medical insurance directory.

Zejing Pharmaceutical (688266.SH): Gicacizidine hydrochloride tablets included in the 2025 National Medical Insurance Drug List.
.png)





